NEW YORK, Sept. 8 Exosome Diagnostics, Inc. todayannounced the formation of its scientific advisory board with the appointmentsof Dennis Brown, Ph.D.; Xandra Breakefield, Ph.D.; and Richard L. Edelson,M.D.
Dr. Brown serves as director of Massachusetts General Hospital's programin membrane biology. He is also associate chief for research affairs ofMassachusetts General Hospital's nephrology division and a professor atHarvard Medical School. He is a renowned expert in the study of proteintrafficking and cell signaling. Dr. Brown earned his Ph.D. in biology fromthe University of East Anglia in England.
Dr. Breakefield is a professor of neurology at Harvard Medical School anda geneticist in neurology and radiology services at Massachusetts GeneralHospital, where she directs the laboratory of experimental gene therapy. Herlaboratory is actively involved in characterizing the role of exosomesproduced by tumor cells in the manipulation of normal tissue to promote tumorexpansion and as serum biomarkers to monitor tumor status. Dr. Breakefieldearned her Ph.D. from Georgetown University.
Dr. Edelson is director of the Yale Cancer Center and a professor at YaleUniversity School of Medicine. He is recognized for his leadership in thestudies of cutaneous T cell lymphoma and its therapeutic management. He haspublished more than 140 original scientific papers, authored or co-authoredmore than 70 review articles, book chapters and five books, and holds 20scientific and therapeutic patents. Dr. Edelson earned his M.D. from YaleUniversity School of Medicine.
"Drs. Brown, Breakefield and Edelson will provide Exosome Diagnostics withinvaluable counsel as we move forward with expanded clinical trials andcommercial launch of a series of blood based diagnostics that profile geneticmutations," said James McCullough, chairman and chief executive officer.
About Exosome Diagnostics
Exosome Diagnostics is a developer of proprietary genetics-baseddiagnostic tests with applications in oncology and endocrinology. Thecompany's core technology is based on the discovery that circulatingnanovesicles called exosomes contain unique genetic markers and that they canbe reliably harvested and used as a diagnostic tool for cancers and metabolicdiseases. Exosome Diagnostics' lead program is a blood-based diagnostic testfor the management of brain tumor patients. For more information, visitwww.exosomedx.com.
SOURCE Exosome Diagnostics, Inc.